Business EconomyPosted at: Jul 7 2026 7:39PM


Reliance arm patents AI blood test for early cancer detection

Bengaluru, July 7 (UNI) In a significant breakthrough for cancer diagnostics, Reliance Industries subsidiary Strand Life Sciences has secured an Indian patent for an artificial intelligence-powered technology that can detect cancer at an early stage from a simple blood sample, potentially paving the way for more accessible and scalable screening across the country.
The patented platform combines cell-free DNA (cfDNA) analysis, advanced genome sequencing, biologically informed methylation and fragmentomic profiling, and machine learning to identify cancer and predict its tissue of origin through a minimally invasive blood test.
The development comes at a time when cancer is emerging as one of India's fastest-growing public health challenges, with more than 1.5 million new cases estimated every year. A large proportion of patients are diagnosed only in advanced stages, when treatment becomes more complex and survival rates decline.
According to Strand Life Sciences, a key innovation behind the patent is its ability to accurately capture genome-wide methylation patterns—one of the strongest biological signatures of cancer—using genome sequencing with minimal loss of information, thereby improving the sensitivity of early detection.
The company believes the technology could help overcome the limitations of conventional cancer screening, which currently covers only a handful of cancers and remains difficult to scale. As genome sequencing becomes more affordable, the platform has the potential to support large-scale population screening without requiring major investments in new healthcare infrastructure.
"Early detection is an increasingly relevant topic as cancer is becoming one of India's greatest public health challenges. This patent reflects our commitment to developing scientifically rigorous, AI-enabled liquid biopsy technologies that can help detect cancer earlier from a simple blood sample," said Ramesh Hariharan, CEO of Strand Life Sciences.
He said the innovation marks an important step towards making precision cancer screening more accurate, scalable and accessible.
The patent further strengthens Strand Life Sciences' intellectual property portfolio in liquid biopsy technologies and reinforces its strategy of developing AI-enabled molecular diagnostics for early cancer detection and precision oncology.
A spin-off from the Indian Institute of Science and now a subsidiary of Reliance Industries, the Bengaluru-based genomics company works with global pharmaceutical, biotechnology and diagnostics firms in research, drug development and precision medicine while expanding its integrated multi-omics capabilities.
UNI BDN
Please log in to get detailed story.
Tags: #Reliance arm patents AI blood test for early cancer detection
More News

Market valuation of five of top-10 most valued firms spikes by Rs 1 54 lakh crore

19 Jul 2026 | 12:09 PM

New Delhi, Jul 19 (UNI) In a week, the market valuation of five of the top-10 most valued firms jumped Rs 1.54 trillion. IT major TCS emerged as the biggest winner, in line with a positive trend in equities. TCS added Rs 72,072.3 crore, taking its market valuation to Rs 8,20,672.70 crore.

see more..

AP: India's largest fashion destination, 'TRENDS' opens store

18 Jul 2026 | 8:14 PM

Guntur, July 18 (UNI) India's largest and fastest growing apparel and accessories specialty chain of Reliance Retail, TRENDS, launched its 7th new Store in Amaravati Road at Guntur in Andhra Pradesh.

see more..

Revanth Reddy announces land for FICCI, reaffirms push for women-led entrepreneurship

18 Jul 2026 | 6:58 PM

Hyderabad, July 18 (UNI) Telangana Chief Minister A Revanth Reddy on Saturday reiterated his government's commitment to women-led development, announcing the allocation of 1,000 square yards of land near Shilparamam in Hitech City for the Federation of Indian Chambers of Commerce and Industry (FICCI) to establish its headquarters and one acre in Bharat Future City to make the organisation a partner in the State's flagship development project.

see more..

Kotak dismisses margin pressure concerns after 26 pc Q1 profit jump

18 Jul 2026 | 5:43 PM

Mumbai, July 18 (UNI) Kotak Mahindra Bank on Saturday sought to allay investor concerns over the quality of its June-quarter earnings after reporting a 26 per cent rise in standalone net profit to ₹4,123 crore, saying its net interest margins (NIM) had stabilised following the Reserve Bank of India's repo rate cycle and that earnings were driven by underlying operating strength rather than merely lower provisioning.

see more..

Kotak Mahindra Bank Q1 profit rises 26 pc as NPAs fall

18 Jul 2026 | 4:17 PM

Mumbai, July 18 (UNI) Kotak Mahindra Bank reported a strong start to the financial year with a 26 per cent jump in standalone net profit to ₹4,123 crore in the first quarter of FY27, supported by robust credit growth, higher deposits and a sharp improvement in asset quality.

see more..